



Dirección: Cra. 53 N° 50-09  
Guarne (Antioquia) COLOMBIA.  
Teléfonos: (57-60-4) 550 00 00 - 403 87 60  
Fax: (57-60-4) 551 31 34  
infocolombia@newstetic.com

## SAFETY DATA SHEET LIDOCAINE 2% SP DPFMFS-003

### 1 PRODUCT IDENTIFICATION

#### 1.1 Chemical name:

- Lidocaine Hydrochloride: 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide;hydrochloride

#### 1.2 Product name:

- Lidocaine Hydrochloride 2% Injectable solution

#### 1.3 Synonyms:

- Lidocaine Hydrochloride: Lidocaine HCl

#### 1.4 Recommended use and restrictions of the product:

- Recommended use: Local anesthetic for dental use
- Restrictions for use: Health care professionals only

#### 1.5 Emergency telephone:

In case of emergency, contact the emergency/poison attention line available in your country/state/province/department

You can also contact New Stetic S.A. Carrera 53 N° 50-09, Medellín-Bogotá, Km 22, Guarne, Antioquia, Colombia. Telephone (604) 550 00 00, ext. 1304 or 1306. Website [www.newstetic.com](http://www.newstetic.com)

### 2 HAZARDS IDENTIFICATIONS

#### 2.1 GHS classification:

| Health                                                           | Environment                              | Physical                                 |
|------------------------------------------------------------------|------------------------------------------|------------------------------------------|
| Not classified as dangerous <sup>1</sup>                         | Not classified as dangerous <sup>1</sup> | Not classified as dangerous <sup>1</sup> |
| <sup>1</sup> substance or mixture exempt from GHS classification |                                          |                                          |

#### 2.2 GHS Label:

| Symbol                                                           | Signal word                              | Hazard statements                        |
|------------------------------------------------------------------|------------------------------------------|------------------------------------------|
| Not classified as dangerous <sup>2</sup>                         | Not classified as dangerous <sup>2</sup> | Not classified as dangerous <sup>2</sup> |
| <sup>2</sup> substance or mixture exempt from GHS classification |                                          |                                          |

#### 2.3 Caution statement:

Not available

| Creation date |         | Written by:                   | Reviewed by:                       |         |
|---------------|---------|-------------------------------|------------------------------------|---------|
| 2011-10-05    |         | Pharmaceutical Analyst        | Anesthetic Quality Assurance Coord |         |
| Class         | Page    | Approved by:                  | Actualization date                 | Version |
| D             | 1 of 11 | Anesthetic Technical Director | 2024-12-06                         | 05      |

REFERENCE DOCUMENT: DPDDPR-003

ACTUALIZATION DATE: 2023-11-29

VERSION: 07



## SAFETY DATA SHEET LIDOCAINE 2% SP DPFMFS-003

### 2.4 Appearance in case of emergency:

Not available

### 2.5 Potential side effects:

Not available

### 2.6 NFPA:

Not available

### 2.7 OSHA state:

Not considered as dangerous for OSHA HCS

## 3 COMPOSITION INFORMATION

Description: Mixture (Pharmaceutical product)

| DANGEROUS COMPONENTS                            |               |            |
|-------------------------------------------------|---------------|------------|
| Common name                                     | Concentration | CAS number |
| Lidocaine Hydrochloride                         | 2%            | 73-78-9    |
| the concentration is considered a trade secret. |               |            |

| NON-DANGEROUS COMPONENTS            |               |               |
|-------------------------------------|---------------|---------------|
| Common name                         | Concentration | CAS number    |
| Mixture of non-hazardous excipients | No applicable | No applicable |

## 4 FIRST AID MEASURES

### 4.1 Emergency procedures and first aid measures in case of:

- Inhalation: In the event of any symptoms, remove from source of exposure and supply fresh air. If symptoms persist, consult a doctor.
- Contac with eyes: Wash with plenty of water for at least 15 minutes with your eyes open. If symptoms persist, consult a doctor.
- Contac with skin: Remove contaminated clothing (if applicable), wash with plenty of soap and water. In case the symptoms persist, consult a doctor.

| Creation date |         | Written by:                   | Reviewed by:                       |         |
|---------------|---------|-------------------------------|------------------------------------|---------|
| 2011-10-05    |         | Pharmaceutical Analyst        | Anesthetic Quality Assurance Coord |         |
| Class         | Page    | Approved by:                  | Actualization date                 | Version |
| D             | 2 of 11 | Anesthetic Technical Director | 2024-12-06                         | 05      |

REFERENCE DOCUMENT: DPDDPR-003

ACTUALIZATION DATE: 2023-11-29

VERSION: 07



## SAFETY DATA SHEET LIDOCAINE 2% SP DPFMFS-003

- Ingestion: Perform mouthwash with water. Do not induce vomiting. If symptoms persist, consult a doctor.

### 4.2 Most important symptoms/effects (acute and/or delayed):

Inadvertent contact with this product may cause irritation, followed by numbness. Ingestion may cause numbness of the tongue and anesthetic effects on the stomach. In clinical use, this product produces numbness when injected.

In normal clinical use, adverse effects may include fever, headaches, agitation, tingling of extremities, general hypotension, bradycardia, dizziness, nausea, vomiting, anemia, back pain, post-operative pain and fetal distress.

Systemic absorption can produce central nervous system (CNS) stimulation and/or CNS depression. CNS depression may progress to coma and cardio-respiratory arrest. Signs of cardiovascular toxicity may include changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance. Toxic blood levels may cause atrioventricular block, ventricular arrhythmias, cardiac arrest, and sometimes death. In addition, decreased cardiac output and arterial blood pressure may occur.

Allergic-type reactions are rare but may occur due to sensitivity to the local anesthetic or to other formulation ingredients. These reactions are characterized by signs such as urticaria, pruritus, erythema, angioneurotic edema (including laryngeal, edema), tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and possibly, anaphylactic-like symptoms (including severe hypotension). Cross sensitivity with other amide-type local anesthetics has been reported.

### 4.3 Antidote:

No available

### 4.4 Information for health care professionals:

It does not require immediate medical attention in normal handling situations. In case of overdose or inappropriate practice, treat symptoms. The safety and efficacy of local anesthetics depend on the appropriate dose, the correct technique, the necessary precautions for administration.

## 5 FIRE-FIGHTING MEASURES

### 5.1 Flammability:

No available

### 5.2 Adequate Extinguishing Media

Water, dry chemical, carbon dioxide, or foam as appropriate for fire and surrounding materials.

| Creation date |         | Written by:                   | Reviewed by:                       |         |
|---------------|---------|-------------------------------|------------------------------------|---------|
| 2011-10-05    |         | Pharmaceutical Analyst        | Anesthetic Quality Assurance Coord |         |
| Class         | Page    | Approved by:                  | Actualization date                 | Version |
| D             | 3 of 11 | Anesthetic Technical Director | 2024-12-06                         | 05      |

REFERENCE DOCUMENT: DPDDPR-003

ACTUALIZATION DATE: 2023-11-29

VERSION: 07



## SAFETY DATA SHEET LIDOCAINE 2% SP DPFMFS-003

### 5.3 Inadecuada Extinguishing Media:

No available

### 5.4 Fire-fighting instructions:

Evacuate the surrounding personnel, extinguish the fire using any of the means described and allow the containers and/or structures exposed to the fire to cool down. Heat can cause expansion or decomposition with violent rupture of the packaging units. Container system materials can emit toxic and/or corrosive fumes when burning.

### 5.5 Fire-fighters protection:

No available

### 5.6 Protection equipment for fire-fighters:

Fire-fighters must wear full emergency equipment and approved positive pressure self-contained breathing apparatus.

## 6 ACCIDENTAL REALESE MEASURES

### 6.1 Techniques, procedures, materials and protective equipment in case of:

- Small Spills: Caution should be exercised to prevent ingestion and eye contact. Clean up spills with normal procedures used for non-hazardous liquids. Absorb spill with inert material, then place in chemical waste container. Clean the surface thoroughly with water to remove residual contamination.
- Large Spills: Caution should be exercised to prevent ingestion and eye contact. Wear safety glasses with side shields and wear impervious gloves to avoid skin contact. Alert the environmental or disaster response authorities. Clean up spills with normal procedures used for non-hazardous liquids. Absorb spill with inert material, then place in chemical waste container. Clean the surface thoroughly with water to remove residual contamination.

### 6.2 Environment cautions:

- Do not allow the product to enter water courses.
- Avoid sewer drainage
- Inform the respective authorities in case of release.

### 6.3 Other information:

- See Section 7 for information on safe handling.

| Creation date |         | Written by:                   | Reviewed by:                       |         |
|---------------|---------|-------------------------------|------------------------------------|---------|
| 2011-10-05    |         | Pharmaceutical Analyst        | Anesthetic Quality Assurance Coord |         |
| Class         | Page    | Approved by:                  | Actualization date                 | Version |
| D             | 4 of 11 | Anesthetic Technical Director | 2024-12-06                         | 05      |

REFERENCE DOCUMENT: DPDDPR-003

ACTUALIZATION DATE: 2023-11-29

VERSION: 07



## SAFETY DATA SHEET LIDOCAINE 2% SP DPFMFS-003

- See Section 8 for information on personal protective equipment.
- See Section 13 for information on final disposal.

### 7 HANDLING AND STORAGE

#### 7.1 Handling:

- Avoid contact with the eyes and skin.
- Wash thoroughly with soap and water after handling.
- Use according to the insert instructions.
- Keep out of the reach of children

#### 7.2 Storage:

- Store in a cool and dry place at temperatures below 30°C
- Store protected from the direct impact of sources of heat and light.
- Store in its original packaging.
- Review product insert.

### 8 EXPOSURE CONTROL AND PERSONAL PROTECTION

#### 8.1 Conditions for exposure control:

No specific controls are required

#### 8.2 Engineering controls:

No specific controls are required

#### 8.3 Personal protection equipment:

- Skin: Waterproof gloves (Material: nitrile or natural rubber), protective clothing (Material: antifuilid, leather or waterproof synthetics)
- Airways: Not normally required. In case of spill or leak, wear a mask.

| Creation date |         | Written by:                   | Reviewed by:                       |         |
|---------------|---------|-------------------------------|------------------------------------|---------|
| 2011-10-05    |         | Pharmaceutical Analyst        | Anesthetic Quality Assurance Coord |         |
| Class         | Page    | Approved by:                  | Actualization date                 | Version |
| D             | 5 of 11 | Anesthetic Technical Director | 2024-12-06                         | 05      |

REFERENCE DOCUMENT: DPDDPR-003

ACTUALIZATION DATE: 2023-11-29

VERSION: 07



Dirección: Cra. 53 N° 50-09  
Guarne (Antioquia) COLOMBIA.  
Teléfonos: (57-60-4) 550 00 00 - 403 87 60  
Fax: (57-60-4) 551 31 34  
infocolombia@newstetic.com

## SAFETY DATA SHEET LIDOCAINE 2% SP DPFMFS-003

- Eyes: Safety glasses with side shields
- Face: Not normally required. In case of spills or leaks wear a mask (Material: acetate)

### 8.4 Exposure parameters:

- Lidocaine Hydrochloride: No available
- Mixture of non-hazardous excipients: No available

## 9 PHYSICAL AND CHEMICAL PROPERTIES

- Appearance: Colorless clear solution
- Odor: Odorless
- Odor threshold: Not applicable
- Physical state: Liquid
- pH: 5.0 to 7.0
- Freezing or melting point:  $\approx 0^{\circ}\text{C}$
- Evaporation rate: Not available
- Initial boiling point and boiling range:  $\approx 100^{\circ}\text{C}$
- Flash point: Not flammable
- Evaporation rate: Not available
- Flammability (solid gas): Not applicable
- Upper/lower flammability or explosive limit: Not applicable
- Vapor pressure: Not available
- Vapor density: Not available
- Specific gravity or relative density:  $\approx 1$
- Solubility: Very soluble

| Creation date |         | Written by:                   | Reviewed by:                       |         |
|---------------|---------|-------------------------------|------------------------------------|---------|
| 2011-10-05    |         | Pharmaceutical Analyst        | Anesthetic Quality Assurance Coord |         |
| Class         | Page    | Approved by:                  | Actualization date                 | Version |
| D             | 6 of 11 | Anesthetic Technical Director | 2024-12-06                         | 05      |

REFERENCE DOCUMENT: DPDDPR-003

ACTUALIZATION DATE: 2023-11-29

VERSION: 07



## SAFETY DATA SHEET LIDOCAINE 2% SP DPFMFS-003

- Partition coefficient n-octanol/water: Not available
- Auto-ignition temperature: Not available
- Decomposition temperature: Not available
- Heat value: Not available
- Particle size: Does not apply
- Volatile organic compound content: Not available
- Softening point: Not applicable
- Pour point: Not available
- Viscosity: Not available
- Bulk density: Not applicable
- Percent volatility: Not available
- Saturated vapor concentration: Not available
- Molecular weight: Not available
- Molecular formula: Not available
- Other: Not applicable

### 10 ESTABILITY AND REACTIVITY

#### 10.1 Chemical stability:

Stable under normal storage and handling conditions

#### 10.2 Possible hazardous reaction:

No known

#### 10.3 Conditions to avoid:

- Avoid exposing to high temperatures

| Creation date |         | Written by:                   | Reviewed by:                       |         |
|---------------|---------|-------------------------------|------------------------------------|---------|
| 2011-10-05    |         | Pharmaceutical Analyst        | Anesthetic Quality Assurance Coord |         |
| Class         | Page    | Approved by:                  | Actualization date                 | Version |
| D             | 7 of 11 | Anesthetic Technical Director | 2024-12-06                         | 05      |

REFERENCE DOCUMENT: DPDDPR-003

ACTUALIZATION DATE: 2023-11-29

VERSION: 07





## SAFETY DATA SHEET LIDOCAINE 2% SP DPFMFS-003

- Avoid exposing to sources of heat and intense light
- Avoid freezing
- Avoid autoclaving
- Avoid using the solution if it shows coloration or precipitate.

### 10.4 Incompatibility materials:

- Avoid contact with water reactive species
- Avoid contact with strong reducing agents

### 10.5 Hazardous decompositions products:

No available

### 10.6 Dangerous polymerization:

No available

## 11 TOXICOLOGICAL INFORMATION

### 11.1 Possible exposure ruts:

- Dermal
- Ingestion
- Eyes

### 11.2 Acute toxicity:

Health effects: In case of exceeding maximum recommended doses, signs such as hypersensitivity, perioral and lingual paresthesia, metallic taste and dizziness, difficulty speaking, diplopia, tinnitus, confusion, restlessness and muscle spasms may occur that progress to neuronal depression and lead to seizures and coma.

### 11.3 Chronic toxicity:

Health effects: Inflammation, neural ischemia, neurotoxicity and cardiac toxicity can occur due to modification of action potentials and ionic currents at the heart level.

| Creation date |         | Written by:                   | Reviewed by:                       |         |
|---------------|---------|-------------------------------|------------------------------------|---------|
| 2011-10-05    |         | Pharmaceutical Analyst        | Anesthetic Quality Assurance Coord |         |
| Class         | Page    | Approved by:                  | Actualization date                 | Version |
| D             | 8 of 11 | Anesthetic Technical Director | 2024-12-06                         | 05      |

REFERENCE DOCUMENT: DPDDPR-003

ACTUALIZATION DATE: 2023-11-29

VERSION: 07





## SAFETY DATA SHEET LIDOCAINE 2% SP DPFMFS-003

### 11.4 Other information:

- Carcinogenicity: This product is not expected to cause carcinogenicity.
- Mutagenicity: This product is not expected to cause mutagenic activity.
- Fertility Toxicity: This product is not expected to cause reproductive or developmental toxicity.
- Specific Target Organ Toxicity: Causes central nervous system effects such as drowsiness, confusion, excitability, and nervousness. The product acts as a depressant of the cardiovascular system.

## 12 ECOLOGICAL INFORMATION

### 12.1 Ecotoxicity:

- Lidocaine Hydrochloride: No available
- Mixture of non-hazardous excipients: No available

### 12.2 Persistence in the environment and degradability:

No available

### 12.3 Bioaccumulation potential

No available

### 12.4 Mobility in soil:

No available

### 12.5 Other adverse effects:

No applicable

## 13 DISPOSAL CONSIDERATIONS

- Do not be disposed of with household garbage.
- Do not allow product to enter sewer system.
- Dispose according to applicable regulations according to the corresponding country/state/province/department

| Creation date |         | Written by:                   | Reviewed by:                       |         |
|---------------|---------|-------------------------------|------------------------------------|---------|
| 2011-10-05    |         | Pharmaceutical Analyst        | Anesthetic Quality Assurance Coord |         |
| Class         | Page    | Approved by:                  | Actualization date                 | Version |
| D             | 9 of 11 | Anesthetic Technical Director | 2024-12-06                         | 05      |

REFERENCE DOCUMENT: DPDDPR-003

ACTUALIZATION DATE: 2023-11-29

VERSION: 07



## SAFETY DATA SHEET LIDOCAINE 2% SP DPFMFS-003

WARNING: Local laws, regulations and restrictions may change or be reinterpreted, and differ from national ones, so the considerations for disposing of the material and its packaging may vary with respect to those indicated in this document.

### 14 TRANSPORT INFORMATION

#### 14.1 Hazardous material:

Not classified as dangerous

#### 14.2 Risk class:

Not classified as dangerous

#### 14.3 UN number:

Not classified as dangerous

#### 14.4 IATA classification:

Not classified as dangerous

#### 14.5 Packing group:

Not classified as dangerous

#### 14.6 Maritime pollutant (Yes/No):

No

### 15 REGULATORY INFORMATION

#### 15.1 Colombia:

- Decree 1496 of 2018: This product is a medicine and is not subject to requirements for classification or control of chemical substances.
- Legend: Keep out of the reach of children

#### 15.2 International:

- Canadian Environmental Protection Act: This product is a drug and is not subject to chemical notification requirements.

| Creation date |          | Written by:                   | Reviewed by:                       |         |
|---------------|----------|-------------------------------|------------------------------------|---------|
| 2011-10-05    |          | Pharmaceutical Analyst        | Anesthetic Quality Assurance Coord |         |
| Class         | Page     | Approved by:                  | Actualization date                 | Version |
| D             | 10 of 11 | Anesthetic Technical Director | 2024-12-06                         | 05      |

REFERENCE DOCUMENT: DPDDPR-003

ACTUALIZATION DATE: 2023-11-29

VERSION: 07



## SAFETY DATA SHEET LIDOCAINE 2% SP DPFMFS-003

- European Inventory of Existing Chemicals (EINECS): This product is a medicine and is not subject to chemical notification requirements.
- European Union (EU REACH): This product is a medicine and is not subject to chemical notification requirements.
- Australian Inventory of Chemicals - This product is a drug and is not subject to chemical notification requirements.
- Inventory of Chemicals and Existing Chemicals in China: This product is a drug and is not subject to chemical notification requirements.
- New and Existing Chemicals in Japan: This product is a drug and is not subject to chemical notification requirements.
- List of Existing Chemicals in Korea: This product is a drug and is not subject to chemical notification requirements.
- Philippine Inventory of Chemicals and Chemical Substances - This product is a drug and is not subject to chemical notification requirements.

### 16 OTHER INFORMATION

The information in this document is based on our current knowledge and is given in good faith, but no express or implied warranty is given, nor is any liability assumed for improper handling of the product. This document is prepared in accordance with:

- Globally Harmonized System of Classification and Labeling of Chemicals - GHS (Globally Harmonized System of Classification and Labeling of Chemicals).
- Colombian technical standard NTC 4435: 2010. Merchandise transports. Material Safety Data Sheets. Preparation.
- Decree 1496 of 2018. By which the Globally Harmonized System (GHS) for the classification and labeling of chemical products is adopted and other provisions on chemical safety are issued.

| Creation date |          | Written by:                   | Reviewed by:                       |         |
|---------------|----------|-------------------------------|------------------------------------|---------|
| 2011-10-05    |          | Pharmaceutical Analyst        | Anesthetic Quality Assurance Coord |         |
| Class         | Page     | Approved by:                  | Actualization date                 | Version |
| D             | 11 of 11 | Anesthetic Technical Director | 2024-12-06                         | 05      |

REFERENCE DOCUMENT: DPDDPR-003

ACTUALIZATION DATE: 2023-11-29

VERSION: 07